The Russian Ministry of Health has registered the maximum selling price for the Erelzi drug, the first and only currently etanercept biosimilar, reports Sandoz, a division of the Novartis group of companies.
In early March, the department issued an order on the state registration of the manufacturer’s maximum selling price for Erelzi in the following forms and dosages:
– solution for subcutaneous administration, 50 mg/ml, 1 ml – syringes (4): marginal price excluding VAT – 31,246,84 rubles;
– subcutaneous solution, 50 mg/ml, 0.5 ml – syringes (4): marginal price excluding VAT – 15 623.42 rubles.
Erelzi is included in the list of vital and most essential drugs (VMED) and is approved for the treatment of diseases such as rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, the axial form of spondyloarthritis, psoriasis.
Sandoz is a pioneer and world leader in the development and production of biosimilars, which currently has eight approved biosimilars worldwide. Erelzi became the fourth biosimilar of Sandoz company registered in Russia, which will expand the choice of therapy for both healthcare specialists and patients in Russia.